Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors

2024-511916-25-00 Protocol PM14-A-001-17 Phase I and Phase II (Integrated) - First administration to humans Ended

Start 4 Sep 2017 · End 22 Aug 2025 · Status Ended · 2 EU/EEA countries · 7 sites · Protocol PM14-A-001-17

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - First administration to humans
Status Ended
Participants planned 150
Countries 2
Sites 7

Advanced Solid Tumors

Key facts

Sponsor
Pharma Mar S.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
4 Sep 2017 → 22 Aug 2025
Decision date (initial)
2024-05-02
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-511916-25-00
EudraCT number
2017-001118-27
ClinicalTrials.gov
NCT05076396

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Solid Tumors

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pharma Mar S.A.

Sponsor organisation
Pharma Mar S.A.
Address
Avenida De Los Reyes 1, Poligono Industrial La Mina Poligono Industrial La Mina
City
Colmenar Viejo
Postcode
28770
Country
Spain

Scientific contact point

Organisation
Pharma Mar S.A.
Contact name
Clinical Development Oncology Unit

Public contact point

Organisation
Pharma Mar S.A.
Contact name
Clinical Development Oncology Unit

Locations

2 EU/EEA countries · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 25 1
Spain Ended 90 6
Rest of world
United States
35

Investigational sites

France

1 site · Ended
Institut Gustave Roussy
DITEP, 114 Rue Edouard Vaillant, 94800, Villejuif

Spain

6 sites · Ended
Hospital Universitario 12 De Octubre
Oncology, Bloque D, Avenida De Cordoba Sn, Madrid
Clinica Universidad De Navarra
Oncology, Calle Marquesado De Santa Marta 1, 28027, Madrid
Hospital General Universitario Gregorio Maranon
Medical Oncology, Calle Del Doctor Esquerdo 46, 28009, Madrid
Hospital Universitario Fundacion Jimenez Diaz
START Madrid-FJD, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitario Hm Sanchinarro
START Madrid-HM CIOCC, Calle Ona 10, 28050, Madrid
Vall D'hebron Institut De Recerca
Medical Oncology, Passeig De La Vall D'hebron 119-129, 08035, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2018-02-22 2018-02-22
Spain 2017-09-04 2025-08-21 2017-09-06 2025-01-29

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-03-19 Spain Acceptable
2024-04-26
2024-04-26
2 SUBSTANTIAL MODIFICATION SM-1 2024-11-15 Spain Acceptable
2025-01-03
2025-01-14
3 SUBSTANTIAL MODIFICATION SM-2 2025-02-19 Spain Acceptable 2025-02-24